Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study

Young-Suk Lim; Chun-Yen Lin; Jeong Heo; Ho Bae; Wan-Long Chuang; Aric Josun Hui; Magdy Elkhashab; Huy Trinh; Susanna Tan; Shuyuan Mo; John F. Flaherty; Vithika Suri; Anuj Gaggar; Mani Subramanian; Tak Yin Owen Tsang; Stephen Ryder; Pietro Andreone; Harry Janssen

Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study

Young-Suk Lim, Chun-Yen Lin, Jeong Heo, Ho Bae, Wan-Long Chuang, Aric Josun Hui, Magdy Elkhashab, Huy Trinh, Susanna Tan, Shuyuan Mo, John F. Flaherty, Vithika Suri, Anuj Gaggar, Mani Subramanian, Tak Yin Owen Tsang, Stephen Ryder, Pietro Andreone, Harry Janssen

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Journal of Hepatology
Volume	73
State	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Lim, Y.-S., Lin, C.-Y., Heo, J., Bae, H., Chuang, W.-L., Hui, A. J., Elkhashab, M., Trinh, H., Tan, S., Mo, S., Flaherty, J. F., Suri, V., Gaggar, A., Subramanian, M., Tsang, T. Y. O., Ryder, S., Andreone, P., & Janssen, H. (2020). Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study. Journal of Hepatology, 73.

@article{cd90babc9a0e461f8a52efe5458ff26f,

title = "Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study",

author = "Young-Suk Lim and Chun-Yen Lin and Jeong Heo and Ho Bae and Wan-Long Chuang and Hui, {Aric Josun} and Magdy Elkhashab and Huy Trinh and Susanna Tan and Shuyuan Mo and Flaherty, {John F.} and Vithika Suri and Anuj Gaggar and Mani Subramanian and Tsang, {Tak Yin Owen} and Stephen Ryder and Pietro Andreone and Harry Janssen",

year = "2020",

language = "American English",

volume = "73",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

}

Lim, Y-S, Lin, C-Y, Heo, J, Bae, H, Chuang, W-L, Hui, AJ, Elkhashab, M, Trinh, H, Tan, S, Mo, S, Flaherty, JF, Suri, V, Gaggar, A, Subramanian, M, Tsang, TYO, Ryder, S, Andreone, P & Janssen, H 2020, 'Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study', Journal of Hepatology, vol. 73.

TY - JOUR

T1 - Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study

AU - Lim, Young-Suk

AU - Lin, Chun-Yen

AU - Heo, Jeong

AU - Bae, Ho

AU - Chuang, Wan-Long

AU - Hui, Aric Josun

AU - Elkhashab, Magdy

AU - Trinh, Huy

AU - Tan, Susanna

AU - Mo, Shuyuan

AU - Flaherty, John F.

AU - Suri, Vithika

AU - Gaggar, Anuj

AU - Subramanian, Mani

AU - Tsang, Tak Yin Owen

AU - Ryder, Stephen

AU - Andreone, Pietro

AU - Janssen, Harry

PY - 2020

Y1 - 2020

M3 - Journal Article

SN - 0168-8278

VL - 73

JO - Journal of Hepatology

JF - Journal of Hepatology

ER -